Colorectal Cancer Stage IV Clinical Trial
Official title:
Impact de la Marge de résection Sur la Survie à Long Terme et le Taux de récidive Des Patients Atteints de Cancers Colorectaux opérés au CHUS Entre 2006 et 2016 Pour Des métastases hépatiques
We retrospectively looks at the impact of the margin status and its size in mm on the recurrence rate in colo-rectal liver metastasis surgery.
Main objective : evaluation the margin status (<1mm, 1-4mm, 5-9mm, >10mm) on the survival and recurrence in colo-rectal liver metastases surgery. Secondary objectives include : Evaluate potentiel effects of neo-adjuvant chemotherapy, portal embolisation, and evaluate potentiel bias such as size and number of liver metastases, TNM status of original tumor, timing between primary and metastasis, and extra-hepatic disease. Methods : A retrospective cohort study is built where all patients undergoing liver surgery for colorectal liver metastases between 2011 and 2015 are analysed. Subjects are separated in groups according to their margin status. The local and distal recurrence rates are measured and well as survival. Data is obtained through our hospital data management system. Inclusion criterias include age over 18, primary colorectal cancer metastatic to the liver, having undergone surgery between 2011 and 2015, available pathology reports with required data, available radiologic follow-up. Exclusion criterias include repeat liver resection, documented grossly positive margins (R2 resection), and unavailable pathologic information and follow-up. Using survival as primary outcome (Kaplan Meier) and considering 25% potential loss to follow-up, we calculated a sample size. Since this a retrospective study, no patient is directly contacted. Data will is handled by the surgery resident responsible for the project as well as by research assistants. Statistical analysis are performed accordingly. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03594448 -
Detection of MSI in Circulating Tumor DNA of Colorectal Carcinoma Patients
|
||
Completed |
NCT03986541 -
AREG, EREG and EGFR: Response to Anti-EGFR Agents in Colorectal Cancer
|
||
Completed |
NCT01570452 -
Matrilysin Expression in Different Stages of Colorectal Tumors
|
N/A | |
Recruiting |
NCT05354817 -
Impact of FOLFIRINOX Chemotherapy in IV Stage Colorectal Cancer Patients Previously Exposed to Irinotecan, Fluoropyrimidine and Oxaliplatin
|
Phase 2 | |
Recruiting |
NCT05576896 -
Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory
|
Phase 2 | |
Completed |
NCT04715061 -
Impact of Aerobic Exercise on Immune Response and Side Effects of Cancer Treatments
|
N/A | |
Terminated |
NCT03149679 -
The p53 Colorectal Cancer Trial
|
Phase 2 | |
Completed |
NCT05550701 -
Prognostic Impact of Increased Lymph Node Yield in Colorectal Cancer Patients With Synchronous Distant Metastasis: a Population-based Study of the US Database and a Chinese Registry
|
||
Enrolling by invitation |
NCT04149613 -
Predictive and Prognostic Value of Inflammatory Markers and microRNA in Stage IV Colorectal Cancer
|
||
Completed |
NCT04425239 -
Intermittent or Continuous Panitumumab Plus FOLFIRI for RAS/B-RAF Wild-type Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT06329700 -
Parenchymal Sparing Hepatectomy in Post-chemotherapy Liver Atrophy
|
||
Recruiting |
NCT05382741 -
Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial
|
Phase 2 | |
Recruiting |
NCT06342440 -
Early Detection of Advanced Adenomas and Colorectal Cancer
|
||
Not yet recruiting |
NCT04917276 -
Treatment Response Prediction System of mCRC Patients Based on CTC
|
||
Not yet recruiting |
NCT06296056 -
Phase I Study of Combined Immune Cell Therapy in Patients With Stage 4 Colorectal Cancer With Metastatic Lesion Who Failed Prior Standard of Care
|
Phase 1 | |
Recruiting |
NCT04714814 -
Mechanisms of Fate Evolution of Colorectal Adenocarcinoma Metastasis
|
||
Not yet recruiting |
NCT05451719 -
Fruquintinib Plus Capecitabine Versus Capecitabine as Maintenance Therapy for Metastatic Colorectal Cancer After First-line Chemotherapy
|
Phase 2 | |
Completed |
NCT03031444 -
Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis
|
Phase 2/Phase 3 | |
Recruiting |
NCT05171660 -
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
|
Phase 3 | |
Recruiting |
NCT05426005 -
Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer
|
Phase 1/Phase 2 |